Pacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.54, $0.34 worse than the analyst estimate of $0.88. Revenue for the quarter came in at $181.2 million versus the consensus estimate of $180.85 million.

GUIDANCE:

Pacira Pharma sees FY2024 revenue of $680-705 million, versus the consensus of $716.6 million.
Non-GAAP gross margin of 74% to 76%;
Non-GAAP R&D expense of $70 million to $80 million;
Non-GAAP SG&A expense of $245 million to $265 million; and
Stock-based compensation of $50 million to $55 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.